JP2009517337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517337A5 JP2009517337A5 JP2008536564A JP2008536564A JP2009517337A5 JP 2009517337 A5 JP2009517337 A5 JP 2009517337A5 JP 2008536564 A JP2008536564 A JP 2008536564A JP 2008536564 A JP2008536564 A JP 2008536564A JP 2009517337 A5 JP2009517337 A5 JP 2009517337A5
- Authority
- JP
- Japan
- Prior art keywords
- assembly
- fab
- antibody
- antigen
- effector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 avimers Proteins 0.000 claims 22
- 239000012636 effector Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 230000000975 bioactive effect Effects 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108700020796 Oncogene Proteins 0.000 claims 5
- 102000006382 Ribonucleases Human genes 0.000 claims 5
- 108010083644 Ribonucleases Proteins 0.000 claims 5
- 239000003102 growth factor Substances 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 4
- 238000006471 dimerization reaction Methods 0.000 claims 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000003032 molecular docking Methods 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 102000043276 Oncogene Human genes 0.000 claims 3
- 102000007327 Protamines Human genes 0.000 claims 3
- 108010007568 Protamines Proteins 0.000 claims 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 208000036552 dowling-degos disease 3 Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 229940048914 protamine Drugs 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101100524547 Arabidopsis thaliana RFS5 gene Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims 2
- 108010008629 CA-125 Antigen Proteins 0.000 claims 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 2
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims 2
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100034263 Mucin-2 Human genes 0.000 claims 2
- 102100022497 Mucin-3A Human genes 0.000 claims 2
- 102100022693 Mucin-4 Human genes 0.000 claims 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 2
- 102100035194 Placenta growth factor Human genes 0.000 claims 2
- 231100000742 Plant toxin Toxicity 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims 2
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 2
- 206010054094 Tumour necrosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000000688 bacterial toxin Substances 0.000 claims 2
- 101150061829 bre-3 gene Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 239000003123 plant toxin Substances 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- WJMFXQBNYLYADA-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-1,2-dihydronaphthalene-2,3-dicarboxylic acid Chemical compound C12=CC(O)=C(O)C=C2C=C(C(O)=O)C(C(=O)O)C1C1=CC=C(O)C(O)=C1 WJMFXQBNYLYADA-UHFFFAOYSA-N 0.000 claims 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims 1
- 108010066676 Abrin Proteins 0.000 claims 1
- 108010051457 Acid Phosphatase Proteins 0.000 claims 1
- 102000013563 Acid Phosphatase Human genes 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 108090000189 Neuropeptides Proteins 0.000 claims 1
- 102000004459 Nitroreductase Human genes 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 101150030083 PE38 gene Proteins 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 108010073038 Penicillin Amidase Proteins 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000013058 Weber syndrome Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 102000006635 beta-lactamase Human genes 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000007293 brain stem infarction Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 229940048921 humira Drugs 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 229950003734 milatuzumab Drugs 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 108020001162 nitroreductase Proteins 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 108700028325 pokeweed antiviral Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 229940116176 remicade Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 229940036185 synagis Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 229940099073 xolair Drugs 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72829205P | 2005-10-19 | 2005-10-19 | |
| US60/728,292 | 2005-10-19 | ||
| US75119605P | 2005-12-16 | 2005-12-16 | |
| US60/751,196 | 2005-12-16 | ||
| US78233206P | 2006-03-14 | 2006-03-14 | |
| US60/782,332 | 2006-03-14 | ||
| US11/389,358 US7550143B2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| PCT/US2006/010762 WO2006107617A2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| USPCT/US2006/010762 | 2006-03-24 | ||
| US11/389,358 | 2006-03-24 | ||
| US11/391,584 | 2006-03-28 | ||
| US11/391,584 US7521056B2 (en) | 2005-04-06 | 2006-03-28 | Stably tethered structures of defined compositions with multiple functions or binding specificities |
| PCT/US2006/012084 WO2006107786A2 (en) | 2005-04-06 | 2006-03-29 | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| USPCT/US2006/012084 | 2006-03-29 | ||
| PCT/US2006/025499 WO2007046893A2 (en) | 2005-10-19 | 2006-06-29 | Methods for generating bioactive assemblies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009517337A JP2009517337A (ja) | 2009-04-30 |
| JP2009517337A5 true JP2009517337A5 (enExample) | 2009-07-02 |
| JP5231231B2 JP5231231B2 (ja) | 2013-07-10 |
Family
ID=40666724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536564A Active JP5231231B2 (ja) | 2005-10-19 | 2006-06-29 | 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1937851A4 (enExample) |
| JP (1) | JP5231231B2 (enExample) |
| AU (1) | AU2006302848C1 (enExample) |
| CA (1) | CA2607056C (enExample) |
| WO (1) | WO2007046893A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US8491914B2 (en) | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US7901680B2 (en) * | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| AU2009233925B2 (en) * | 2006-12-05 | 2014-03-13 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| BRPI0915093A2 (pt) | 2008-06-13 | 2015-10-27 | Proyecto Biomedicina Cima Sl | conjugados para a administração de compostos biologicamente ativos |
| US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
| CN102325790A (zh) | 2008-12-03 | 2012-01-18 | 西马生物医学计划公司 | 应用酚可溶性调控蛋白研制疫苗 |
| WO2010091324A1 (en) * | 2009-02-06 | 2010-08-12 | Western States Biopharmaceuticals, Inc. | Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members |
| US8535477B2 (en) | 2009-02-21 | 2013-09-17 | Sofradim Production | Medical devices incorporating functional adhesives |
| EP2258398A1 (en) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
| JP6114936B2 (ja) * | 2009-08-31 | 2017-04-19 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法 |
| CN102481348A (zh) * | 2009-08-31 | 2012-05-30 | Ibc药品公司 | 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途 |
| US20120237535A1 (en) | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| AU2010315432A1 (en) * | 2009-11-05 | 2012-04-12 | Center For Molecular Medicine And Immunology | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
| EP2509630A4 (en) * | 2009-12-09 | 2013-07-17 | Immunomedics Inc | SYSTEM FOR PROCESSING CYTOTOXIC REMEDIES THROUGH BISPECIFIC ANTIBODY TARGET |
| CA2781717C (en) * | 2009-12-09 | 2017-09-12 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) complexes for delivery of interference rna |
| US10822396B2 (en) | 2009-12-15 | 2020-11-03 | MuHyeon CHOE | Repeat-chain for the production of dimer, multimer, multimer complex and super-complex |
| EP2518078B1 (en) * | 2009-12-15 | 2020-05-20 | Choe, Muhyeon | Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers |
| JP5786204B2 (ja) * | 2010-01-19 | 2015-09-30 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| EP2588525A4 (en) | 2010-06-29 | 2015-06-10 | Covidien Lp | MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD |
| WO2012001532A2 (en) | 2010-07-01 | 2012-01-05 | Sofradim Production | Medical device with predefined activated cellular integration |
| CA2808211C (en) * | 2010-08-17 | 2018-08-28 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| AU2011323354B2 (en) * | 2010-11-03 | 2014-07-31 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
| EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
| CN103160513B (zh) * | 2011-12-16 | 2015-07-01 | 中国医学科学院基础医学研究所 | Muc1蛋白核酸适配子、复合体、组合物及其用途 |
| EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
| EP2854845B1 (en) | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
| CN102703453B (zh) * | 2012-06-13 | 2013-10-30 | 江南大学 | 特异性识别链霉素的dna适配体及其应用 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| ITRM20130138A1 (it) | 2013-03-07 | 2014-09-08 | Consiglio Nazionale Ricerche | Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica |
| US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
| WO2015065987A1 (en) | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| FR3017714A1 (fr) * | 2014-02-18 | 2015-08-21 | Biomerieux Sa | Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| NZ726520A (en) | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| CN104558174A (zh) * | 2015-01-29 | 2015-04-29 | 东南大学 | 一种针对睾酮的特异性纳米抗体及其应用 |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| EP3303370A4 (en) | 2015-05-28 | 2019-03-13 | Immunomedics, Inc. | T20-CONSTRUCTS FOR THERAPY AND / OR VACCINES AGAINST HIV (HUMAN IMMUNODEFICIENCY VIRUS) |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN116333138A (zh) | 2015-07-30 | 2023-06-27 | 宏观基因有限公司 | Pd-1结合分子和其使用方法 |
| IL258521B2 (en) | 2015-10-08 | 2024-01-01 | Macrogenics Inc | Combination therapy for the treatment of cancer |
| CN108289920A (zh) * | 2015-10-12 | 2018-07-17 | 汉阳大学校产学协力团 | 用于基因转移和基因治疗的腺病毒复合物 |
| AU2016364431B2 (en) * | 2015-12-04 | 2020-08-27 | Zenyaku Kogyo Co., Ltd. | Anti-IL-17 aptamer having improved retention in blood |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| WO2017142928A1 (en) | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP4653464A2 (en) | 2016-12-23 | 2025-11-26 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
| EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
| WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
| CN109771658B (zh) * | 2017-11-14 | 2021-12-10 | 博瑞生物医药（苏州）股份有限公司 | 靶向多臂偶联物 |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| AU2019222666B2 (en) | 2018-02-15 | 2025-12-04 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
| KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| US12252582B2 (en) | 2019-08-29 | 2025-03-18 | University Of Delaware | Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices |
| EP4106813A4 (en) | 2020-02-21 | 2024-03-27 | MacroGenics, Inc. | CD137 BINDING MOLECULES AND THEIR USES |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| US20240279353A1 (en) | 2020-07-06 | 2024-08-22 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| CN112156194B (zh) * | 2020-09-29 | 2023-01-24 | 中国工程物理研究院核物理与化学研究所 | 一种去除177Lu溶液中内毒素的方法 |
| WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| CN115976196B (zh) * | 2022-12-16 | 2024-12-06 | 深圳市人民医院 | ErbB3作为肺动脉高压生物标志物和治疗靶点的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
| JP4113670B2 (ja) * | 1998-06-22 | 2008-07-09 | イムノメディクス， インコーポレイテッド | プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用 |
| US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
| CA2503787A1 (en) * | 2002-11-05 | 2004-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of isolation of active compounds and activated targets |
| WO2004072287A1 (en) * | 2003-02-13 | 2004-08-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
| CN101484182B (zh) * | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| CN105709237A (zh) * | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
-
2006
- 2006-06-29 JP JP2008536564A patent/JP5231231B2/ja active Active
- 2006-06-29 CA CA2607056A patent/CA2607056C/en active Active
- 2006-06-29 AU AU2006302848A patent/AU2006302848C1/en active Active
- 2006-06-29 EP EP06785922A patent/EP1937851A4/en not_active Withdrawn
- 2006-06-29 WO PCT/US2006/025499 patent/WO2007046893A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009517337A5 (enExample) | ||
| JP2008538747A5 (enExample) | ||
| JP2008542194A5 (enExample) | ||
| JP7062025B2 (ja) | 修飾ｊ鎖 | |
| JP5011277B2 (ja) | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 | |
| JP5231231B2 (ja) | 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用 | |
| JP2009519931A5 (enExample) | ||
| Wang et al. | Silencing Fc domains in T cell–engaging bispecific antibodies improves T-cell trafficking and antitumor potency | |
| JP6746845B2 (ja) | 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け | |
| US20100143356A1 (en) | Therapeutic and diagnostic anti-hsp70 antibodies | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN101374546A (zh) | 基于多价免疫球蛋白的生物活性装配体 | |
| JP2007524686A5 (enExample) | ||
| Homayouni et al. | Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3) | |
| JP2008542194A (ja) | 多機能または多結合特異性を有する、改善した安定なテザー構造体の規定された組成物 | |
| JP2008523795A (ja) | 抗体フォーマットの生産および前記抗体フォーマットの免疫学的用途 | |
| CN114634569A (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| JP2020188762A (ja) | 細胞の細胞質への分子の送達のための構築物 | |
| CN117916271A (zh) | Her2单域抗体变体及其car | |
| JP2005510470A (ja) | 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物 | |
| WO2024022516A1 (zh) | 抗cd28人源化单域抗体 | |
| WO2025067496A1 (zh) | 靶向baff-r的全人源抗体、car-t细胞及其应用 | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| CN103159857B (zh) | 以重组的三股螺旋支架为基础的复合物 | |
| Benmebarek | Characterization of bispecific antibodies that drive synthetic agonistic receptor-transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models |